354.MU - Collegium Pharmaceutical Inc

Munich - Munich Delayed Price. Currency in EUR
20.60
0.00 (0.00%)
At close: 08:01AM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close20.60
Open20.60
Bid20.00 x N/A
Ask20.20 x N/A
Day's Range20.60 - 20.60
52 Week Range14.70 - 27.00
Volume54
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 02, 2023 - Aug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 354.MU

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Collegium to Participate in Jefferies Healthcare Conference

      STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023. Details of the event are as follows:Fireside Chat Date and Time: Thursday, June 8, 2023, at 12:30 p.m. ET T

    • Investopedia

      Top Pharmaceutical Stocks for Q2 2023

      Aclaris Therapeutics, Collegium Pharmaceutical, and Intra-Cellular Therapies lead the industry in quarterly revenue growth

    • Insider Monkey

      Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Call Transcript

      Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Call Transcript May 6, 2023 Operator: Greetings and welcome to the Collegium Pharmaceutical First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note that this conference call is being recorded. I will […]

    • Zacks

      Collegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to Say

      Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

    • Zacks

      Collegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates

      Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    • GlobeNewswire

      Collegium Reports First Quarter 2023 Financial Results

      – Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca® and Xtampza® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today r

    • Zacks

      Pacira (PCRX) Lags Q1 Earnings Estimates

      Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    • Zacks

      Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

      Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    • GlobeNewswire

      Collegium to Report First Quarter 2023 Financial Results on May 4, 2023

      STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Informa

    • GlobeNewswire

      Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference

      STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 18, 2023, at 2:15 p

    • Zacks

      COLL vs. ZTS: Which Stock Should Value Investors Buy Now?

      COLL vs. ZTS: Which Stock Is the Better Value Option?

    • Zacks

      Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall

      Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.

    • Insider Monkey

      Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Call Transcript

      Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Greetings, and welcome to the Collegium Pharmaceutical Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note, that this conference call is being […]

    • Thomson Reuters StreetEvents

      Q4 2022 Collegium Pharmaceutical Inc Earnings Call

      Q4 2022 Collegium Pharmaceutical Inc Earnings Call

    • Zacks

      Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

      Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

    • GlobeNewswire

      Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

      – Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial r

    • Zacks

      Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down

      Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.

    • GlobeNewswire

      Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report

      Highlights 2022 environmental, social and governance achievementsSTOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report. The report reflects the Company’s long-standing commitment to operating with integrity, accountability and responsibility in all facets of its business while improving the health and

    • Zacks

      Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know

      Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    • Zacks

      Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

      Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    • Zacks

      COLL or ZTS: Which Is the Better Value Stock Right Now?

      COLL vs. ZTS: Which Stock Is the Better Value Option?

    • GlobeNewswire

      Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering

      STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amoun

    • GlobeNewswire

      Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

      STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Collegium also expects to grant the initial purchaser of the notes an option to purc

    • GlobeNewswire

      Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

      -Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a pivotal year for Collegium Pharmace

    • Zacks

      Zacks.com featured highlights MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical

      MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical have been highlighted in this Screen of The Week article.